Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Bifulco

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Bioorganic & Medicinal Chemistry|June 6, 2003
Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitorsWieslaw Kazmierski, Neil Bifulco, Hanbiao Yang, et al.
Cancer Discovery|March 18, 2015
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling PathwayMargit Hagel, Chandra Miduturu, Michael Sheets, et al.
Cancer Discovery|October 3, 2019
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular CarcinomaMegan A Hatlen, Oleg Schmidt-Kittler, Cori Ann Sherwin, et al.
Gastro Hep Advances|August 12, 2024
Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar CarcinomaStefanie S Schalm, Erin O'Hearn, Kevin Wilson, et al.
Bioorganic & Medicinal Chemistry Letters|November 9, 2005
Substituted indanylacetic acids as PPAR-alpha-gamma activatorsDerek B Lowe, Neil Bifulco, William H Bullock, et al.
Nature Microbiology|July 1, 2017
ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumanniiThomas F Durand-Réville, Satenig Guler, Janelle Comita-Prevoir, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Bioorganic & Medicinal Chemistry|June 6, 2003
Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitorsWieslaw Kazmierski, Neil Bifulco, Hanbiao Yang, et al.
Cancer Discovery|March 18, 2015
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling PathwayMargit Hagel, Chandra Miduturu, Michael Sheets, et al.
Cancer Discovery|October 3, 2019
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular CarcinomaMegan A Hatlen, Oleg Schmidt-Kittler, Cori Ann Sherwin, et al.
Gastro Hep Advances|August 12, 2024
Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar CarcinomaStefanie S Schalm, Erin O'Hearn, Kevin Wilson, et al.
Bioorganic & Medicinal Chemistry Letters|November 9, 2005
Substituted indanylacetic acids as PPAR-alpha-gamma activatorsDerek B Lowe, Neil Bifulco, William H Bullock, et al.
Nature Microbiology|July 1, 2017
ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumanniiThomas F Durand-Réville, Satenig Guler, Janelle Comita-Prevoir, et al.
Pageof 1